Single-dose intravenous valproate in acute mania

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• High-dose valproate (oral and intravenous) has demonstrated therapeutic effects in mania within 48-72 hours.
• The rapid onset of action seen with intravenous valproate in status epilepticus prompted investigation into faster antimanic effects.

Purpose of the Study:

• To investigate the hypothesis that very high-dose intravenous valproate could produce rapid antimanic effects within 20 minutes.
• To evaluate the safety and efficacy of rapid, high-dose intravenous valproate administration in acute mania.

Main Methods:

• Seven patients diagnosed with mania (Young Mania Rating Scale score > 20) and minimal prior treatment were enrolled.
• Valproate was administered intravenously at a dose of 20 mg/kg over 30 minutes.
• Patients were observed for 120 minutes for any antimanic effects or adverse events.

Main Results:

• No observable antimanic effects were detected within the 120-minute observation period.
• The rapid, high-dose intravenous administration of valproate was well-tolerated, with no reported side effects.
• This suggests that the rapid administration of valproate does not yield immediate therapeutic benefits in acute mania.

Conclusions:

• The antimanic effects of anticonvulsants like valproate may necessitate slower biochemical alterations, potentially involving gene-level modifications.
• Rapid intravenous administration of valproate is not effective for acute manic episodes.
• Further research is needed to understand the temporal dynamics of valproate's antimanic mechanisms.